Long-term results of induction chemotherapy for non-operable esophageal squamous cell carcinoma followed by concurrent chemoradiotherapy: a single-centre experience

Xiang, Geng; Chai, Guangjin; Lyu, Bo; Li, Zhaohui; Yin, Yutian; Wang, Bin; Pan, Yanglin; Shi, Mei; Zhao, Lina

doi:10.2478/raon-2024-0038

Abstract

Background

This study aimed to investigate the long-term clinical outcomes and toxicities of induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) vs. CCRT alone in patients with non-operable esophageal squamous cell carcinoma (ESCC).

Patients and methods

Between 2008 and 2022, 271 ESCC patients who received definitive CCRT based on intensity modulated radiation therapy (IMRT)/volumetric modulated arc therapy (VMAT) were enrolled. Through a propensity score-matched (PSM) method, 71 patients receiving IC and CCRT were matched 1:1 to patients who received CCRT alone. The Kaplan-Meier method and Cox proportional hazards model were applied to analyze survival and prognosis.

Results

The IC + CCRT group had no improvement in 5-year overall survival (OS) rate, recurrence-free survival (RFS) rate, and distant metastasis-free survival (DMFS) rate (all p > 0.05) compared with the CCRT group. The 5-year OS rate (65.6% vs. 17.6% vs. 29.3%, p < 0.001), RFS rate (65.6% vs. 17.6% vs. 26.9%, p < 0.001), and DMFS rate (62.5% vs. 10.3% vs. 27.2%, p < 0.001) of the IC good responders were significantly higher than that of the IC poor responders and CCRT group. Multivariate analysis revealed that total radiotherapy time (≥ 49 days) and stage III/IV were independent predictive factors of OS, RFS, and DMFS. No significant differences were observed in the rates of grade 3–4 toxicities between both groups.

Conclusions

Our results showed the addition of IC to CCRT was not superior to CCRT in unselected ESCC patients, while IC responders could benefit from this regime without an increase in toxicities.

References

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics 2021. CA Cancer J Clin 2021; 71: 7–33. doi: 10.3322/caac.21654
Open DOI Search in Google Scholar Back to article
Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P, et al. Oesophageal cancer. Nat Rev Dis Primers 2017; 3: 17048. doi: 10.1038/nrdp.2017.48
Open DOI Search in Google Scholar Back to article
Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut 2015; 64: 381–7. doi: 10.1136/gutjnl-2014-308124
Open DOI Search in Google Scholar Back to article
Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet 2017; 390: 2383–96. doi: 10.1016/S0140-6736(17)31462-9
Open DOI Search in Google Scholar Back to article
Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson Jr JA, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281: 1623–7. doi: 10.1001/jama.281.17.1623
Open DOI Search in Google Scholar Back to article
Gwynne S, Hurt C, Evans M, Holden C, Vout L, Crosby T. Definitive chemoradiation for oesophageal cancer: a standard of care in patients with non-metastatic oesophageal cancer. Clin Oncol 2011; 23: 182–8. doi: 10.1016/j.clon.2010.12.001
Open DOI Search in Google Scholar Back to article
Xi M, Xu C, Liao ZX, Hofstetter WL, Murphy MB, Maru DM, et al. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol 2017; 124: 318–24. doi: 10.1016/j.radonc.2017.06.019
Open DOI Search in Google Scholar Back to article
Sudo K, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Taketa T, et al. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol 2014; 32: 3400–5. doi: 10.1200/JCO.2014.56.7156
Open DOI Search in Google Scholar Back to article
Liu SL, Luo LL, Zhao L, Zhu YJ, Liu H, Li QQ, et al. Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial. Nat Commun 2021; 12: 4014. doi: 10.1038/s41467-021-24288-1
Open DOI Search in Google Scholar Back to article
Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomized controlled trial. Lancet Oncol 2016; 17: 1509–20. doi: 10.1016/S1470-2045(16)30410-7
Open DOI Search in Google Scholar Back to article
Chen MQ, Lin QL, Chen YG, Guo JH, Xu BH, Tian Y. Neoadjuvant chemotherapy may not benefit esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. J Chin Med Assoc 2017; 80: 636. doi: 10.1016/j.jcma.2017.06.014
Open DOI Search in Google Scholar Back to article
Luo LL, Xi M, Yang YD, Li QQ, Zhao L, Zhang P, et al. Comparative outcomes of induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma. J Cancer 2017; 8: 3441–7. doi: 10.7150/jca.21131
Open DOI Search in Google Scholar Back to article
Akinori M, Michitaka H, Yousuke I, Tsuyoshi K, Tairo R, Gencho K, et al. Induction chemotherapy followed by chemoradiotherapy for T4M0 esophageal cancer. Esophagus 2011; 8: 31–7. doi: 10.1007/s10388-011-0255-y
Open DOI Search in Google Scholar Back to article
Jin J, Liao ZX, Zhang Z, Ajani J, Swisher S, Chang JY, et al. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 2004; 60: 427–36. doi: 10.1016/j.ijrobp.2004.03.033
Open DOI Search in Google Scholar Back to article
Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Rice DC, et al. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer 2006; 107: 967–74. doi: 10.1002/cncr.22077
Open DOI Search in Google Scholar Back to article
Li C, Wang X, Wang L, Chen JQ, Zhang WC, Pang QS, et al. Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey. Acta Oncologica 2021; 60: 627–34. doi: 10.1080/0284186X.2021.1902564
Open DOI Search in Google Scholar Back to article
Lyu B, Yin YT, Zhao YL, Yang X, Gong J, Zhang M, et al. Long-term clinical outcomes and safety analysis of superficial esophageal cancer patients treated with definitive or adjuvant radiotherapy. Cancers 2022; 14: 3423. doi: 10.3390/cancers14143423
Open DOI Search in Google Scholar Back to article
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–47. doi: 10.1016/j.ejca.2008.10.026
Open DOI Search in Google Scholar Back to article
Wang JN, Xiao LL, Wang S, Pang QS, Wang J. Addition of induction or consolidation chemotherapy in definitive concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for patients with unresectable esophageal cancer: a systematic review and meta-analysis. Front Oncol 2021; 11: 665231. doi: 10.3389/fonc.2021.665231
Open DOI Search in Google Scholar Back to article
Wu HS, Yu YL, Zheng QH, Liu TX, Wu YH, Wang ZP, et al. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma. Radiat Oncol 2021; 16: 1–14. doi: 10.1186/s13014-021-01931-1
Open DOI Search in Google Scholar Back to article
Hsieh JCH, Chiang PC, Hung TM, Chao YK, Kuo YC, Wen CT, et al. Definitive concurrent chemoradiotherapy with paclitaxel plus carboplatin is superior to cisplatin plus 5-fluorouracil in patients with inoperable esophageal squamous cell carcinoma using retrospective, real-world evidence. Cancer Med 2021; 10: 8300–9. doi: 10.1002/cam4.4025
Open DOI Search in Google Scholar Back to article
Sher DJ, Posner MR, Tishler RB, Sarlis NJ, Haddad RI, Holupka EJ, et al. Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324. Int J Radiat Oncol Biol Phys 2011; 81: 813–8. doi: 10.1016/j.ijrobp.2010.12.005
Open DOI Search in Google Scholar Back to article
Cannon DM, Geye HM, Hartig GK, Traynor AM, Hoang T, McCulloch TM, et al. Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemotherapy. Head Neck 2014; 36: 1120–5. doi: 10.1002/hed.23419
Open DOI Search in Google Scholar Back to article
Xu C, Xi M, Moreno A, Shiraishi Y, Hobbs BP, Huang ML, et al. Definitive chemoradiation therapy for esophageal cancer in the elderly: clinical outcomes for patients exceeding 80 years old. Int J Radiat Oncol Biol Phys 2017; 98: 811–9. doi: 10.1016/j.ijrobp.2017.02.097
Open DOI Search in Google Scholar Back to article
Cai YL, Lin YX, Jiang LS, Ye H, Li FY, Cheng NS. A novel nomogram predicting distant metastasis in T1 and T2 gallbladder cancer: a SEER-based study. Int J Med Sci 2020; 17: 1704–12. doi: 10.7150/ijms.47073
Open DOI Search in Google Scholar Back to article
Colzani E, Johansson ALV, Liljegren A, Foukakis T, Clements M, Adolfsson J, et al. Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics. Br J Cancer 2014; 110: 1378–84. doi: 10.1038/bjc.2014.5
Open DOI Search in Google Scholar Back to article
Hemminki K, Pavlidis N, Tsilidis KK, Sundquist K, Ji J. Age-dependent metastatic spread and survival: Cancer of unknown primary as a model. Sci Rep 2016; 6: 23725. doi: 10.1038/srep23725
Open DOI Search in Google Scholar Back to article
Kumabe A, Zenda S, Motegi A, Onozawa M, Nakamura N, Kojima T, et al. Long-term clinical results of concurrent chemoradiotherapy for patients with cervical esophageal squamous cell carcinoma. Anticancer Res 2017; 37: 5039–44. doi: 10.21873/anticanres.11919
Open DOI Search in Google Scholar Back to article
Minsky BD, Neuberg D, Kelsen DP, Pisansky TM, Ginsberg RJ, Pajak T, et al. Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 1999; 43: 517–23. doi: 10.1016/s0360-3016(98)00463-5
Open DOI Search in Google Scholar Back to article
Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999; 17: 2915–21. doi: 10.1200/JCO.1999.17.9.2915
Open DOI Search in Google Scholar Back to article
Shinoda M, Ando N, Kato K, Ishikura S, Kato H, Tsubosa Y, et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci 2015; 106: 407–12. doi: 10.1111/cas.12622
Open DOI Search in Google Scholar Back to article
Chan C, Lang S, Rowbottom C, Guckenberger M, Faivre-Finn C. Intensity-modulated radiotherapy for lung cancer: current status and future developments. J Thorac Oncol 2014; 9: 1598–608. doi: 10.1097/JTO.0000000000000346
Open DOI Search in Google Scholar Back to article